Improved Characterization of Focal Liver Lesions With Liver-Specific Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging: A Multicenter Phase 3 Clinical Trial

Objectives: To evaluate the safety of gadoxetic acid disodium (Gd-EOB-DTPA) magnetic resonance imaging (MRI) and its efficacy in characterizing liver lesions. Methods: Lesion characterization and classification using combined (unenhanced and Gd-EOB-DTPA-enhanced) MRI were compared with those using unenhanced MRI and contrast-enhanced spiral computed tomography (CT) using on-site clinical and off-site blinded evaluations for patients with focal liver lesions. Results: Gadoxetic acid disodium was well tolerated in this study. For the clinical evaluation, more lesions were correctly characterized using combined (unenhanced and Gd-EOB-DTPA-enhanced) MRI than using unenhanced MRI and spiral CT (96% vs 84% and 85%, respectively; P ≤ 0.0008). For the blinded evaluation, more lesions were correctly characterized using combined MRI compared with using unenhanced MRI (61%-76% vs 48%-65%, respectively; P ≤ 0.0012 for 2/3 readers); when compared with spiral CT, a similar proportion of lesions were correctly characterized. Conclusions: Gadoxetic acid disodium-enhanced MRI is of clinical benefit relative to unenhanced MRI and spiral CT for a radiological diagnosis of liver lesions.

[1]  Michael Laniado,et al.  Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions , 2008, European Radiology.

[2]  Caroline Reinhold,et al.  Liver Tumor Characterization: Comparison Between Liver-specific Gadoxetic Acid Disodium-enhanced MRI and Biphasic CT-A Multicenter Trial , 2006, Journal of computer assisted tomography.

[3]  J. Mintorovitch,et al.  Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths , 2005, Investigative radiology.

[4]  D. Sahani,et al.  Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. , 2005, Radiology.

[5]  R. Semelka,et al.  Contrast agents for MR imaging of the liver. , 2005, Radiologic clinics of North America.

[6]  P. Robinson,et al.  Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. , 2004, Radiology.

[7]  W F Bennett,et al.  Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging , 2000, Journal of magnetic resonance imaging : JMRI.

[8]  S. Kondo,et al.  Preoperative embolization of the common hepatic artery in preparation for radical pancreatectomy for pancreas body cancer. , 2000, Hepato-gastroenterology.

[9]  P. Robinson,et al.  Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. , 2000, Radiology.

[10]  P. Mergo,et al.  Characterization of focal hepatic lesions with ferumoxides-enhanced T2-weighted MR imaging. , 2000, AJR. American journal of roentgenology.

[11]  G. Marchal,et al.  Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study. , 2000, Radiology.

[12]  E. Rummeny,et al.  MnDPDP for MR imaging of the liver , 1997, Acta radiologica.

[13]  Contrast agents for MR imaging of the liver , 1997, Journal of magnetic resonance imaging : JMRI.

[14]  M. Mack,et al.  Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. , 1996, Radiology.

[15]  E. Rummeny,et al.  Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. , 1996, Radiology.

[16]  M. Baker,et al.  Hepatic metastases: basic principles and implications for radiologists. , 1995, Radiology.

[17]  S E Seltzer,et al.  Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. , 1995, Radiology.

[18]  M. Taupitz,et al.  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. , 1995, Radiology.

[19]  D. Mitchell,et al.  Hepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-enhanced MR imaging. , 1994, Radiology.

[20]  M Lüning,et al.  Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. , 1994, Radiology.

[21]  R. Jeffrey,et al.  Dynamic breath-hold multiplanar spoiled gradient-recalled MR imaging with gadolinium enhancement for differentiating hepatic hemangiomas from malignancies at 1.5 T. , 1993, Radiology.

[22]  R. Brasch,et al.  Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats. , 1992, Investigative radiology.

[23]  H. Weinmann,et al.  Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. , 1992, Radiology.

[24]  H. Weinmann,et al.  A new lipophilic gadolinium chelate as a tissue‐specific contrast medium for MRI , 1991, Magnetic resonance in medicine.

[25]  A Donner,et al.  Application of the McNemar test to non-independent matched pair data. , 1991, Statistics in medicine.

[26]  M. Reiser,et al.  Detection of hepatic masses in patients with carcinoma: comparative sensitivities of sonography, CT, and MR imaging. , 1991, AJR. American journal of roentgenology.

[27]  P. Sugarbaker.  Surgical decision making for large bowel cancer metastatic to the liver. , 1990, Radiology.

[28]  J. Heiken,et al.  Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging. , 1989, Radiology.

[29]  Y. Morioka,et al.  Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis. , 1987 .